Tirzepatide

Tirzepatide — Tirze-Pep by Dragon Pharma

Tirze-Pep is Dragon Pharma's formulation of Tirzepatide at 5mg per vial — a dual GLP-1/GIP receptor agonist and one of the most extensively studied peptides for appetite control, glucose regulation and weight management. Supplied as a lyophilised vial requiring reconstitution, Tirze-Pep is dosed via weekly subcutaneous injection.

Also searched as: Tirzepatide 5mg, GLP-1 GIP peptide, Tirze-Pep Dragon Pharma, tirzepatide vial.

What Is Tirzepatide?

Tirzepatide is a synthetic peptide that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors — a dual mechanism that distinguishes it from single-action GLP-1 compounds. This combined receptor activity slows gastric emptying, increases satiety, and improves insulin sensitivity, resulting in significant appetite reduction and supporting substantial reductions in body weight in clinical research. Tirzepatide does not interact with androgen receptors or the HPG axis and does not suppress natural testosterone production.

Effects and Benefits

• Significant appetite reduction — most users report a marked decrease in hunger and food intake within the first 1-2 weeks
• Slowed gastric emptying, contributing to prolonged satiety after meals
• Improved insulin sensitivity and glucose regulation
• Substantial body weight reduction supported by extensive clinical research at therapeutic doses
• No suppression of natural testosterone — does not require Post Cycle Therapy

Dosage and Administration

Tirzepatide is dosed once weekly via subcutaneous injection, with the dose typically titrated upward gradually every 4 weeks to minimise gastrointestinal side effects. The 5mg Tirze-Pep vial provides flexibility for both starting doses (drawing a partial dose) and standard maintenance dosing at the full 5mg mark. For users requiring higher maintenance doses, Dragon Pharma also offers Tirzepatide 10mg.